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Cancer metabolism has long been equated with aerobic glycolysis, seen by early biochemists as primitive
and inefficient. Despite these early beliefs, themetabolic signatures of cancer cells are not passive responses
to damaged mitochondria but result from oncogene-directed metabolic reprogramming required to support
anabolic growth. Recent evidence suggests that metabolites themselves can be oncogenic by altering cell
signaling and blocking cellular differentiation. No longer can cancer-associated alterations in metabolism
be viewed as an indirect response to cell proliferation and survival signals. We contend that altered metab-
olism has attained the status of a core hallmark of cancer.The propensity for proliferating cells to secrete a significant frac-
tion of glucose carbon through fermentation was first elucidated
in yeast. Otto Warburg extended these observations to mamma-
lian cells, finding that proliferating ascites tumor cells converted
the majority of their glucose carbon to lactate, even in oxygen-
rich conditions. Warburg hypothesized that this altered metab-
olism was specific to cancer cells, and that it arose from
mitochondrial defects that inhibited their ability to effectively
oxidize glucose carbon to CO2. An extension of this hypothesis
was that dysfunctional mitochondria caused cancer (Koppenol
et al., 2011). Warburg’s seminal finding has been observed in
a wide variety of cancers. These observations have been ex-
ploited clinically using 18F-deoxyglucose positron emission
tomography (FDG-PET). However, in contrast to Warburg’s orig-
inal hypothesis, damaged mitochondria are not at the root of the
aerobic glycolysis exhibited by most tumor cells. Most tumor
mitochondria are not defective in their ability to carry out oxida-
tive phosphorylation. Instead, in proliferating cells, mitochondrial
metabolism is reprogrammed to meet the challenges of macro-
molecular synthesis. This possibility was never considered by
Warburg and his contemporaries.
Advances in cancer metabolism research over the last decade
have enhanced our understanding of how aerobic glycolysis and
other metabolic alterations observed in cancer cells support the
anabolic requirements associated with cell growth and prolifera-
tion. It has become clear that anabolic metabolism is under
complex regulatory control directed by growth-factor signal
transduction in nontransformed cells. Yet despite these
advances, the repeated refrain from traditional biochemists is
that altered metabolism is merely an indirect phenomenon in
cancer, a secondary effect that pales in importance to the activa-
tion of primary proliferation and survival signals (Hanahan and
Weinberg, 2011). Most proto-oncogenes and tumor suppressor
genes encode components of signal transduction pathways.
Their roles in carcinogenesis have traditionally been attributed
to their ability to regulate the cell cycle and sustain proliferative
signaling while also helping cells evade growth suppression
and/or cell death (Hanahan and Weinberg, 2011). But evidence
for an alternative concept, that the primary functions of activatedoncogenes and inactivated tumor suppressors are to reprogram
cellular metabolism, has continued to build over the past several
years. Evidence is also developing for the proposal that proto-
oncogenes and tumor suppressors primarily evolved to regulate
metabolism.
We begin this review by discussing how proliferative cell
metabolism differs from quiescent cell metabolism on the basis
of active metabolic reprogramming by proto-oncogenes and
tumor suppressors. Much of this reprogramming depends on
utilizing mitochondria as functional biosynthetic organelles. We
then further develop the idea that alteredmetabolism is a primary
feature selected for during tumorigenesis. Recent advances
have demonstrated that altered metabolism in cancer extends
beyond adaptations to meet the increased anabolic require-
ments of a growing and dividing cell. Changes in cancer cell
metabolism can also influence cellular differentiation status,
and in some cases these changes arise from oncogenic alter-
ations in metabolic enzymes themselves.
Quiescent versus Proliferating Cells: Both Use
Mitochondria, but to Different Ends
Most nonproliferating, differentiated cells depend on the effi-
ciency of ATP production through oxidative phosphorylation to
maintain their integrity. As a result, such cells metabolize glucose
to pyruvate through glycolysis, and then completely oxidizemost
of this pyruvate to CO2 through the tricarboxylic acid (TCA) cycle
of the mitochondria, where oxygen is the final acceptor in an
electron transport chain that generates an electrochemical
gradient facilitating ATP production. The elucidation of the TCA
cycle and how cells maximize ATP production to maintain them-
selves was one of the great discoveries of the last century.
In vivo, metazoan cells are surrounded by an abundance of
nutrients. However, unlike prokaryotes or single-cell eukaryotes,
animal cells are not cell autonomous for nutrient uptake. Instead,
just to survive, metazoan cells compete for limiting levels of
growth factors that direct nutrient uptake (Rathmell et al.,
2000). To survive under such conditions, differentiated cells
adopt a catabolic metabolism focused on maximizing the effi-
ciency of ATP production from limited nutrients (DeberardinisCancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 297
Figure 1. Metabolism in Quiescent versus Proliferating Cells: Both
Use Mitochondria
(A) In the absence of instructional growth factor signaling, cells in multicellular
organisms lack the ability to take up sufficient nutrients to maintain them-
selves. Neglected cells will undergo autophagy and catabolize amino acids
and lipids through the TCA cycle, assuming sufficient oxygen is available. This
oxidative metabolism maximizes ATP production.
(B) Cells that receive instructional growth factor signaling are directed to
increase their uptake of nutrients, most notably glucose and glutamine. The
increased nutrient uptake can then support the anabolic requirements of cell
growth: mainly lipid, protein, and nucleotide synthesis (biomass). Excess
carbon is secreted as lactate. Proliferating cells may also use strategies to
decrease their ATP production while increasing their ATP consumption. These
strategies maintain the ADP:ATP ratio necessary to sustain glycolytic flux.
Green arrows represent metabolic pathways, while black arrows represent
signaling.
Figure 2. Metabolism Is a Direct, Not Indirect, Response to Growth
Factor Signaling
(A) The traditional demand-based model of how metabolism is altered in
proliferating cells. In response to growth factor signaling, increased tran-
scription and translation consume free energy and decrease the ATP:ADP
ratio. This leads to enhanced flux of glucose carbon through glycolysis and the
TCA cycle for the purpose of producing more ATP.
(B) Supply-based model of how metabolism changes in proliferating cells.
Growth factor signaling directly reprograms nutrient uptake and metabolism.
Increased nutrient flux through glycolysis and the mitochondria in response to
growth factor signaling is used for biomass production. Metabolism also
impacts transcription and translation through mechanisms independent of
ATP availability.et al., 2006; Lum et al., 2005; Vander Heiden et al., 2009)
(Figure 1A). In contrast, when growth factors are abundant, cells
increase their nutrient uptake and adopt an anabolic metabolism
(Bauer et al., 2004) (Figure 1B). As a consequence of intracellular
abundance of nutrients, growth-factor-stimulated cells adapt to
their largesse by initiating cell division in a manner analogous to
that of single-cell eukaryotes exposed to nutrient-rich medium
(Boer et al., 2010; Conlon and Raff, 2003; Fantes and Nurse,
1977). In cancer cells, the instructional signaling pathways
downstream of growth factor receptors can be constitutively
activated in the absence of extracellular growth factors.
Altered Metabolism Is a Direct Response
to Growth-Factor Signaling
The traditional cancer model posits that the altered metabolism
associated with cell proliferation occurs as a secondary re-298 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.sponse to cell cycle and proliferative signaling. In this model,
the demand for free energy to sustain transcription and transla-
tion drives a decrease in the ATP:ADP ratio, leading to subse-
quent allosteric effects on rate-limiting metabolic enzymes
(Figure 2A). While traditional allosteric regulation certainly occurs
in proliferating cells, strong evidence now exists to support an
alternative model. In this supply-based model, changes in meta-
bolic fluxes occur in primary response to growth-factor
signaling, independent of changes in ATP and othermechanisms
worked out by early biochemists (Figure 2B). The reprogramming
of cellular metabolism toward macromolecular synthesis is crit-
ical to supplying enough nucleotides, proteins, and lipids for
a cell to double its total biomass and then divide to produce
two daughter cells. In contrast to the catabolic metabolism of
differentiated cells, this anabolic metabolism fundamental to
cell growth and proliferation is not focused on maximizing ATP
Figure 3. Alterations in Classic Oncogenes Directly Reprogram Cell
Metabolism to Increase Nutrient Uptake and Biosynthesis
PI3K/Akt signaling downstream of receptor tyrosine kinase (RTK) activation
increases glucose uptake through the transporter GLUT1, and increases flux
through glycolysis. Branches of glycolytic metabolism contribute to nucleotide
and amino acid synthesis. Akt also activates ATP-citrate lyase (ACL),
promoting the conversion of mitochondria-derived citrate to acetyl-CoA for
lipid synthesis. Mitochondrial citrate can be synthesized when glucose-
derived acetyl-CoA, generated by pyruvate dehydrogenase (PDH), condenses
with glutamine-derived oxaloacetate (OAA) via the activity of citrate synthase
(CS). mTORC1 promotes protein synthesis and mitochondrial metabolism.
Myc increases glutamine uptake and the conversion of glutamine into a mito-
chondrial carbon source by promoting the expression of the enzyme gluta-
minase (GLS). Myc also promotes mitochondrial biogenesis. In addition, Myc
promotes nucleotide and amino acid synthesis, both through direct tran-
scriptional regulation and through increasing the synthesis of mitochondrial
metabolite precursors.yield. Rather than ATP, proliferating cells are in much greater
need of reduced carbon and reduced nitrogen, as well as cyto-
solic NADPH for reductive biosynthetic reactions.
The recognition that proliferating cells do not maximize ATP
production through mitochondrial oxidative phosphorylation
has contributed to the continuing misconception that prolifer-
ating cells, particularly cancer cells, do not utilize mitochondria.
In fact, most cancer cells and proliferating normal cells still derive
a significant fraction of their ATP through oxidative phosphoryla-
tion. However, in proliferating cells, in contrast to quiescent cells,
this oxidative phosphorylation-dependent production of ATP
appears secondary to the use of mitochondrial enzymes in the
synthesis of anabolic precursors.
PI3K/Akt/mTORC1 Activation: Driving Anabolic
Metabolism and Tumorigenesis by Reprogramming
Mitochondria
Activation of the PI3K/Akt pathway is perhaps themost common
lesion in spontaneous human cancers. Activated PI3K/Akt leads
to enhanced glucose uptake and glycolysis (Buzzai et al., 2005;
Elstromet al., 2004). Pivotal to this induction is increased glucose
transporter expression on the cell surface, activation of hexoki-
nase to capture glucose intracellularly through phosphorylation,
and Akt-induced, phosphofructokinase-2-dependent allosteric
activation of phosphofructokinase-1 to commit glucose to glyco-
lytic metabolism (Deprez et al., 1997; Gottlob et al., 2001; Kohn
et al., 1996; Rathmell et al., 2003). However, the PI3K/Akt
pathway also promotes glucose carbon flux into biosynthetic
pathways that rely upon functional mitochondrial metabolism
(Figure 3). For example, fatty acid, cholesterol, and isoprenoid
synthesis all require acetyl-CoA (Wakil et al., 1957). The pyruvate
dehydrogenase (PDH) complex that converts glucose-derived
pyruvate into acetyl-CoA is solely mitochondrial (Linn et al.,
1969). Mitochondrial acetyl-CoA then cannot be directly ex-
ported to the cytoplasm but instead must first condense with
oxaloacetate to form citrate through the activity of another exclu-
sively mitochondrial enzyme, citrate synthase (Stern et al., 1952).
Citrate can then be exported to the cytosol, where it can be con-
verted back to acetyl-CoA by ATP-citrate lyase (ACL) (Srere,
1959). Akt facilitates this diversion of mitochondrial citrate from
the TCA cycle to acetyl-CoA production by phosphorylating
and activating ACL (Bauer et al., 2005; Berwick et al., 2002;
Hatzivassiliou et al., 2005). RNAi knockdown or pharmacologic
inhibition of ACL is particularly effective at decreasing the
in vitro proliferation of cells with increased glucose uptake. ACL
knockdown can also diminish Akt-driven tumorigenesis in vivo
(Bauer et al., 2005; Hatzivassiliou et al., 2005). ACL’s breakdown
of citrate is also pivotal to preventing a cytosolic accumulation of
citrate. Citrate is a major negative allosteric regulator of glycol-
ysis (Stryer, 1995). Taken together, these findings demonstrate
that the reprogramming of mitochondrial citrate metabolism is
a central aspect of PI3K/Akt oncogenic activity.
Downstream of PI3K/Akt, the well-characterized cell growth
regulator mTORC1 also has many effects intertwined with mito-
chondrial metabolism. mTORC1 is best known for enhancing
protein synthesis. Several amino acid precursors are derived
from the transamination of mitochondrial intermediates. Oxalo-
acetate can be transaminated to produce aspartate which can
serve as a precursor for asparagine, and a-ketoglutarate can betransaminated to produce glutamate, which in turn can be con-
verted to proline, arginine, and glutamine. Most cancers depend
on these syntheses rather than exogenous supplies. This is
consistent with how most tumors other than childhood leukemia
are resistant to the effects of depleting the blood of asparagine
through the intravenous use of L-asparaginase (Clarkson et al.,
1970; Tallal et al., 1970). mTORC1 has also been shown to have
direct effects on promoting mitochondrial biogenesis, in part via
a transcriptional complex that promotes the function of PGC-1a
(Bentzinger et al., 2008; Cunningham et al., 2007; Ramanathan
and Schreiber, 2009; Schieke et al., 2006). Finally, a study
isolating the cell-intrinsic consequences of mTORC1 activation
demonstrated that SREBP-mediated de novo lipogenesis is
a critical component of mTORC1-driven proliferation (Du¨vel
et al., 2010). As discussed above, de novo lipogenesis in
mammalian cells depends on mitochondrial citrate production.
HIF-1-Mediated Inhibition of Carbon Flux into
Mitochondria Can Be Antiproliferative
Notably, Du¨vel et al. (2010) found that the other major target of
mTORC1 activation, hypoxia-inducible factor 1 (HIF-1), is notCancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 299
critical for mTORC1-driven proliferation. This may seem
surprising in light of HIF-1’s often-cited ability to promote the
enhanced glycolysis characteristic of cancer cells. However,
HIF-1 activation has the additional effect of inhibiting mitochon-
drial metabolism of glucose carbon, in part by promoting the
expression of pyruvate dehydrogenase kinase 1 (PDK1) to inhibit
PDH activity (Kim et al., 2006; Papandreou et al., 2006). By
diverting pyruvate into lactate, HIF-1 blocks glucose carbon
incorporation into mitochondrial citrate which is critical for lipid
synthesis (Lum et al., 2007). This block correlates with the anti-
proliferative effect of HIF-1 observed in hematopoietic and renal
cells (Lum et al., 2007) and fits with recent genetic evidence of
HIF-1 acting as a tumor suppressor in some cancers (Shen
et al., 2011).
There are cancers that do exhibit decreased flux of glucose-
derived pyruvate into themitochondria relative to normal tissues.
However, as will be discussed later in this review, these cancers
still rely on mitochondrial metabolic flux. In place of oxidative
metabolism of both glucose and glutamine, these cancers pref-
erentially perform reductive and carboxylating biosynthetic reac-
tions from glutamine carbon (Le et al., 2012; Metallo et al., 2012;
Mullen et al., 2012; Wise et al., 2011).
Myc Activation Also Impacts Mitochondrial Metabolism
Like PI3K, Akt, and mTORC1, the Myc transcription factor has
important metabolic roles beyond enhancing glycolysis. Myc
promotes mitochondrial gene expression and mitochondrial
biogenesis (Li et al., 2005). Oncogenic Myc has also been shown
to promote the mitochondrial utilization of glutamine by
enhancing the expression of glutaminase (GLS), which deami-
dates glutamine to glutamate. Cells expressing oncogenic Myc
are glutamine-addicted and undergo apoptosis when glutamine
is withdrawn from the culture medium. While the role of gluta-
mine as a nitrogen donor is important for the proliferation of
these cells, their viability depends on glutamine as a carbon
source for mitochondrial metabolism (DeBerardinis et al., 2007;
Fan et al., 2010; Gao et al., 2009; Wise et al., 2008; Yuneva
et al., 2007). Recently, it was observed that the growth of tumor
xenografts from Myc-expressing B cells can be impaired by
pharmacological inhibition of GLS (Le et al., 2012). These data
provide further evidence that reprogrammed glutamine metabo-
lism is critical to the growth and survival of Myc-drivenmalignan-
cies. Upstream of Myc, RhoGTPases have also been linked to
the activation of GLS and glutamine dependence. Either siRNA
knockdown or pharmacological inhibition of GLS can inhibit
Rho-GTPase-induced transformation and proliferation (Wang
et al., 2010).
Did Proto-Oncogenes and Tumor Suppressors Arise
in Evolution as Components of Metabolic Regulation?
The weight of the evidence to date supports the concept that re-
programming of cellular metabolism is a primary and funda-
mental aspect of transformation resulting from mutations in
proto-oncogenes and tumor suppressors. Proliferative metabo-
lism is heavily dependent on the reprogramming of mitochondria
to serve a synthetic rather than a degradative role. Metabolic
changes associated with proliferating cells do not simply occur
passively in response to damaged mitochondria or changes in
ATP levels.300 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.A related concept concerns the possibility that proto-onco-
genes and tumor suppressors arose in evolution as components
of metabolic regulation. Consistent with this hypothesis, activa-
tion of the tumor suppressor p53 has been shown to be critical
for cell survival following glucose depletion (Jones et al., 2005).
Subsequent reports have linked this metabolic stress response
of p53 to increased fatty acid oxidation (Assaily et al., 2011;
Zaugg et al., 2011). In tumors, the loss of p53 can enhance
glycolysis and anabolic synthesis from glycolytic intermediates
(Bensaad et al., 2006; Kondoh et al., 2005; Matoba et al.,
2006). However, mitochondrial metabolism continues to be crit-
ical in cells with metabolic reprogramming arising from p53 loss.
Treatment with the antidiabetic drug metformin, an inhibitor of
complex 1 of the mitochondrial electron transport chain (El-Mir
et al., 2000; Owen et al., 2000), is especially toxic to p53-defi-
cient tumor cells (Buzzai et al., 2007).
Oncogenic mutations in proto-oncogenes can be selected for
in tumor populations subjected to metabolic stress. Yun et al.
(2009) showed that depriving colon carcinoma cells of glucose
increased the rate at which activating mutations in Ras grew
out. Surviving clones were better able to cope with limited
glucose due to their upregulation of the transporter GLUT1.
Some clones demonstrated KRAS mutations, and mutant
KRAS was shown to upregulate GLUT1 expression and confer
sensitivity to glycolytic inhibition. Importantly, increased
glycolytic metabolism from activated Ras does not stem from
defective mitochondrial pathways. Even for Ras-mediated
tumorigenesis, the importance of intact mitochondrial oxidative
metabolism has been confirmed in vivo (Guo et al., 2011; Wein-
berg et al., 2010).
Metabolic Enzymes Can Be Alternatively Spliced
to Isoforms that Support Anabolic Growth
In addition to activating oncogenes like Ras, preferentially ex-
pressing specific isoforms of metabolic enzymes can provide
cancer cells with a mechanism to select for metabolic alterations
during tumorigenesis. For example, proliferating cells almost
universally express the M2 isoform of pyruvate kinase M
(PKM2). Pyruvate kinase is a glycolytic enzyme that converts
phosphoenolpyruvate (PEP) to pyruvate, with concomitant
generation of ATP. In contrast to the M1 isoform of pyruvate
kinase (PKM1) that is the predominant isoform in most adult
differentiated tissues, the PKM2 splice variant is the major iso-
form in embryonic tissues and in all cancer cells examined to
date (Mazurek, 2011). Other significant genes for proliferative
cell metabolism are also alternatively spliced. The phosphofruc-
tokinase/fructose-2,6-bisphosphatase B3 gene (PFKFB3) is
highly expressed in human tumors and has six splice variants.
Two splice variants predominate in high-grade astrocytoma
and colon carcinoma and enhance glycolytic flux, while other
splice variants are limited to low-grade tumors and normal
tissues (Bando et al., 2005; Zscharnack et al., 2009). An alterna-
tively spliced isoform of GLS may also be important for the
mitochondrial glutamine metabolism of tumor cells (Cassago
et al., 2012).
The most extensively characterized of these alternatively
splicedmetabolic enzymes remains pyruvate kinase. The prefer-
ential expression of PKM2 in proliferating cells suggested a pro-
tumorigenic role for this splice variant, and xenograft models
Figure 4. Pyruvate Kinase M2 Expression in Proliferating Cells Is
Regulated by Signaling and Mitochondrial Metabolism to Facilitate
Macromolecular Synthesis
Pyruvate kinase M2 (PKM2) is a less active isoform of the terminal glycolytic
enzyme pyruvate kinase. It is also uniquely inhibited downstream of tyrosine
kinase signaling. The decreased enzymatic activity of PKM2 in the cytoplasm
promotes the accumulation of upstream glycolytic intermediates and their
shunting into anabolic pathways. These pathways include the serine synthetic
pathway that contributes to nucleotide and amino acid production. When
mitochondrial metabolism is excessive, reactive oxygen species (ROS) from
the mitochondria can feed back to inhibit PKM2 activity. Acetylation of PKM2,
dependent on acetyl-CoA availability, may also promote PKM2 degradation
and further contribute to increased flux through anabolic synthesis pathways
branching off glycolysis.subsequently demonstrated that PKM2-expressing cells have
a growth advantage in vivo compared with PKM1-expressing
cells (Christofk et al., 2008a). However, in whatmight seem para-
doxical for an isoform associated with proliferating and highly
glycolytic cells, PKM2 has intrinsically lower enzymatic activity
than PKM1. PKM2 is also uniquely sensitive to inhibition by tyro-
sine kinase signaling downstream of growth factor receptors, in
contrast to PKM1 which is constitutively active (Christofk et al.,
2008b; Hitosugi et al., 2009). Current evidence suggests that
the decreased activity of PKM2 is selected to facilitate anabolic
metabolism (Figure 4). With less rapid conversion of PEP to pyru-
vate, the accumulation of upstream glycolytic intermediates and
subsequent shunting of these intermediates into anabolic path-
ways branching off glycolysis can result. These pathways
include pyrimidine biosynthesis (Mazurek et al., 2001). They
may also include the glycerol synthesis and serine/glycine
synthesis pathways.
The Primary Role of PKM2 Expression in Proliferating
Cells Is to Facilitate Anabolic Metabolism
Accompanying the resurgence of interest in the metabolic
effects of PKM2 have been recent reports on ‘‘non-metabolic’’
functions of PKM2 (Luo et al., 2011; Yang et al., 2011). These
studies are the latest variations on a theme from work spanning
over a decade that have identified at least 11 proteins that bind to
PKM2 (Garcia-Gonzalo et al., 2003; Le Mellay et al., 2002; Ma-
zurek et al., 2001, 2007; Shimada et al., 2008; Siwko and
Mochly-Rosen, 2007; Spoden et al., 2009; Williams et al.,
1998; Wu et al., 2008; Zwerschke et al., 1999). Several of these
are nuclear proteins, suggesting that PKM2 may, under certain
conditions, translocate to the nucleus to fulfill nonmetabolic,
putatively transcriptional functions (Hoshino et al., 2007; Ignacak
and Stachurska, 2003; Lee et al., 2008; Spoden et al., 2008;
Steta´k et al., 2007). However, other studies have added further
strength to the concept that reduced pyruvate kinase enzymatic
activity in the cytoplasm, leading to enhanced anabolic metabo-
lism from glycolytic intermediates, is the primary role for PKM2
expression in proliferating cells. A recent study showed that in
cancer cells, elevation of reactive oxygen species (ROS) can
inactivate the active, tetrameric form of the cytosolic PKM2
enzyme (Anastasiou et al., 2011). Another report showed that
PKM2 has a unique lysine residue which is acetylated in tumor
cells, targeting it for degradation by chaperone-mediated auto-
phagy (Lv et al., 2011). Both of these findings are consistent
with PKM2 primarily acting as a glycolytic switch that can be
rapidly inactivated in tumor cells by multiple mechanisms, all of
which facilitate the shunting of glucose carbon/glycolytic inter-
mediates into branching anabolic pathways.
A major paradox remaining with PKM2 is that cells expressing
PKM2 produce more glucose-derived pyruvate than PKM1-
expressing cells, despite having a form of the pyruvate kinase
enzyme that is less active and more sensitive to inhibition. One
way to get around the PKM2 bottleneck and maintain/enhance
pyruvate production may be through a proposed alternative
glycolytic pathway involving an enzymatic activity not yet puri-
fied that dephosphorylates PEP to pyruvate without the genera-
tion of ATP (Vander Heiden et al., 2010). Another answer to this
paradox may emanate from the serine synthetic pathway. The
decreased enzymatic activity of PKM2 can promote the accu-mulation of the 3-phosphoglycerate glycolytic intermediate
that serves as the entry point for the serine synthetic pathway
branch off glycolysis. The little-studied enzyme serine dehydra-
tase can then directly convert serine to pyruvate. A third expla-
nation may lie in the oscillatory activity of PKM2 from the
inactive dimer to the active tetramer form. Regulatory inputs
into PKM2 like tyrosine phosphorylation and ROS destabilize
the tetrameric form of PKM2 (Anastasiou et al., 2011; Christofk
et al., 2008b; Hitosugi et al., 2009), but other inputs present in
glycolytic cancer cells like fructose-1,6-bisphosphate and
serine can continually allosterically activate and/or promote
reformation of the PKM2 tetramer (Ashizawa et al., 1991; Eigen-
brodt et al., 1983). Thus, PKM2 may be continually switching
from inactive to active forms in cells, resulting in an apparent
upregulation of flux through anabolic glycolytic branching
pathways while also maintaining reasonable net flux of glucose
carbon through PEP to pyruvate. With such an oscillatory
system, small changes in the levels of any of the above-
mentioned PKM2 regulatory inputs can cause exquisite, rapid
adjustments to glycolytic flux. This would be predicted to be
advantageous for proliferating cells in the setting of variable
extracellular nutrient availability. The capability for oscillatory
regulation of PKM2 could also provide an explanation for why
tumor cells do not select for altered glycolytic metabolismCancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 301
upstream of PKM2 through deletions and/or loss-of-function
mutations of other glycolytic enzymes.
Amplification of Metabolic Enzymes in Cancer
In addition to regulation by alternative splicing, the expression of
metabolic enzymes may also be regulated by increases in gene
copy number in cancer cells. The gene encoding hexokinase II,
which catalyzes the first reaction of glycolysis converting
glucose to glucose-6-phosphate, is amplified in hepatoma cells
(Rempel et al., 1996), and fatty acid synthase has been reported
to exhibit copy-number gain in prostate cancer (Shah et al.,
2006). More recently, two independent groups have identified
amplification of the gene encoding phosphoglycerate dehydro-
genase in breast cancer and melanoma, resulting in increased
flux through the serine/glycine synthesis pathway (Locasale
et al., 2011; Possemato et al., 2011). As described above, the
expression of PKM2 may provide an independent mechanism
to enhance flux through the serine/glycine synthesis pathway.
This enhanced flux may provide multiple metabolic advantages
in addition to serine and glycine production. One proposed func-
tion is facilitating a-ketoglutarate production for mitochondrial
metabolism (Possemato et al., 2011). Additional proposed func-
tions include the generation of precursors for pyrimidine
synthesis and the production of sarcosine, a glycine-derived
metabolite linked to prostate cancer progression (Sreekumar
et al., 2009; Zhang et al., 2012). Other important functions for
flux through the serine synthesis pathway are likely.
Oncogenic Mutations in Metabolic Enzymes:
The Discovery of IDH1 Mutations and the
Oncometabolite 2-Hydroxyglutarate
While the preference for all tumor cells to express PKM2 versus
PKM1 is striking and likely selected for to facilitate anabolic
metabolism, PKM2 is present in most proliferating cells and is
not specific to cancer (Mazurek, 2011). The strongest evidence
to date that altered metabolism is selected for by cancer cells
during tumorigenesis has come with the recent elucidation of
somatic mutations in metabolic enzymes. Mutations in the cyto-
solic NADP+-dependent isocitrate dehydrogenase 1 gene (IDH1)
were first found to be recurrent in glioma and acute myeloid
leukemia (AML) through whole-genome sequencing (Mardis
et al., 2009; Parsons et al., 2008). The initially described muta-
tions were remarkably selective for a specific arginine residue
in the enzyme active site, R132. All mutations were missense,
and all mutations were heterozygous with retention of the re-
maining wild-type IDH1 allele. These characteristics suggested
that themutants acquired an altered function. Yet this contrasted
with initial data demonstrating that the tumor-specific mutations
in IDH1 and IDH2 resulted in loss of their normal enzymatic
activity to interconvert isocitrate and a-ketoglutarate (Yan
et al., 2009). The heterozygous nature of the mutations was
then explained awaywith the report that IDH1mutants can domi-
nantly inhibit the wild-type IDH1 in cells (Zhao et al., 2009).
An alternative explanation came with the report that IDH1
mutations at R132 are not simply loss-of-function mutations for
isocitrate and a-ketoglutarate interconversion, but also acquire
a novel reductive activity to convert a-ketoglutarate to 2-hy-
droxyglutarate (2HG), a rare metabolite found only in trace
amounts in mammalian cells under normal conditions (Dang302 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.et al., 2009). However, it still remained unclear whether 2HG
was truly a pathogenic ‘‘oncometabolite’’ resulting from IDH1
mutation or was just the byproduct of a loss-of-function muta-
tion. Whether 2HG production or the loss of IDH1 normal func-
tion played a more important role in tumorigenesis remained
uncertain.
2HG Is a Biomarker and Common Feature of Both IDH1
and IDH2 Mutations
A potential answer to whether 2HG production was relevant to
tumorigenesis arrived with the study of mutations in IDH2, the
mitochondrial homolog of IDH1. Up to this point a small fraction
of gliomas lacking IDH1 mutations were known to harbor muta-
tions at IDH2 R172, the analogous residue to IDH1 R132 (Yan
et al., 2009). However, given the rarity of these IDH2 mutations,
they had not been characterized for 2HG production. The
discovery of IDH2 R172 mutations in AML as well as glioma
samples prompted the study of whether these mutations also
conferred the reductive enzymatic activity to produce 2HG.
Enzymatic assays and measurement of 2HG levels in primary
AML samples confirmed that these IDH2 R172 mutations result
in 2HG elevation (Gross et al., 2010; Ward et al., 2010).
It was then investigated whether the measurement of 2HG
levels in primary tumor samples with unknown IDH mutation
status could serve as a metabolite screening test for both cyto-
solic IDH1 andmitochondrial IDH2mutations. AML samples with
low to undetectable 2HG were subsequently sequenced and
determined to be IDH1 and IDH2 wild-types, and several
samples with elevated 2HG were found to have neomorphic
mutations at either IDH1 R132 or IDH2 R172 (Gross et al.,
2010). However, some 2HG-elevated AML samples lacked
IDH1 R132 or IDH2 R172 mutations. When more comprehensive
sequencing of IDH1 and IDH2 was performed, it was found that
the common feature of this remaining subset of 2HG-elevated
AMLs was another mutation in IDH2, occurring at R140 (Ward
et al., 2010). This discovery provided additional evidence that
2HG production was the primary feature being selected for in
tumors.
In addition to intensifying efforts to find the cellular targets of
2HG, the discovery of the 2HG-producing IDH1 and IDH2 muta-
tions suggested that 2HGmeasurementmight have clinical utility
in diagnosis and disease monitoring. While much work is still
needed in this area, serum 2HG levels have successfully corre-
lated with IDH1 R132 mutations in AML, and recent data have
suggested that 1H magnetic resonance spectroscopy can be
applied for 2HG detection in vivo for glioma (Andronesi et al.,
2012; Choi et al., 2012; Gross et al., 2010; Pope et al., 2012).
These methods may have advantages over relying on invasive-
solid-tumor biopsies or isolating leukemic blast cells to obtain
material for sequencing of IDH1 and IDH2. Screening tumors
and body fluids by 2HG status also has potentially increased
applicability given the recent report that additional IDH muta-
tions can produce 2HG (Ward et al., 2011). These additional
alleles may account for the recently described subset of 2HG-
elevated chondrosarcoma samples that lacked the most
common IDH1 or IDH2 mutations but were not examined for
other IDH alterations (Amary et al., 2011). Metabolite screening
approaches can also distinguish neomorphic IDH mutations
from SNPs and sequencing artifacts with no effect on IDH
Figure 5. IDH1 and IDH2 Mutants Convert Glutamine Carbon to the
Oncometabolite 2-Hydroxyglutarate to Dysregulate Epigenetics and
Cell Differentiation
(A) a-ketoglutarate, produced in part by wild-type isocitrate dehydrogenase
(IDH), can enter the nucleus and be used as a substrate for dioxygenase
enzymes that modify epigenetic marks. These enzymes include the TET2 DNA
hydroxylase enzyme, which converts 5-methylcytosine to 5-hydrox-
ymethylcytosine, typically at CpG dinucleotides. 5-hydroxymethylcytosine
may be an intermediate in either active or passive DNA demethylation.
a-ketoglutarate is also a substrate for JmjC domain histone demethylase
enzymes that demethylate lysine residues on histone tails.
(B) The common feature of cancer-associated mutations in cytosolic IDH1 and
mitochondrial IDH2 is the acquisition of a neomorphic enzymatic activity. This
activity converts glutamine-derived a-ketoglutarate to the oncometabolite
2HG. 2HG can competitively inhibit a-ketoglutarate-dependent enzymes like
TET2 and the JmjC histone demethylases, thereby impairing normal epige-
netic regulation. This results in altered histone methylation marks, in some
cases DNA hypermethylation at CpG islands, and dysregulated cellular
differentiation.enzyme activity, as well as from an apparently rare subset of
loss-of-function, non-2HG-producing IDH mutations that may
play a secondary tumorigenic role in altering cellular redox
(Ward et al., 2011).
Metabolites as Oncogenes: Dysregulating Epigenetics
and Cellular Differentiation
Consideration of the tumor subtypes where IDH mutations were
most prevalent, the finding that IDH mutations occurred early in
disease progression (Watanabe et al., 2009), and the lack of
evidence that 2HG was acting as a mutagen (Mardis et al.,
2009) led to investigation of whether 2HG accumulation might
lead to impairment in cellular differentiation. Evidence in support
of this hypothesis was first provided in 32D myeloid cells and in
mouse primary bone marrow cells cultured ex vivo. In both cell
types, the overexpression of IDH mutants blocked acquisition
of mature myeloid markers while increasing the expression of
stem-cell markers (Figueroa et al., 2010).
How could a small organic acid, 2HG, mediate such an effect?
Numerous reports have now highlighted the ability of 2HG to
inhibit several a-ketoglutarate-dependent dioxygenase
enzymes (Figure 5). Contradictory claims exist regarding the
ability of 2HG to inhibit the prolyl hydroxylase that targets
HIF-1 for degradation (PHD2) to modulate HIF levels in cells.
Several independent groups have failed to observe a direct link
between 2HG and PHD2 inhibition. The weight of the evidence
now suggests that regulation of HIF-1 stability through
decreased PHD2 activity is not the primary effect of IDH muta-
tions (Chowdhury et al., 2011; Dang et al., 2009; Jin et al.,
2011; Mardis et al., 2009; Metellus et al., 2011; Williams et al.,
2011). In contrast, multiple groups have found that IDH mutant
expression and 2HG elevation can inhibit the TET family of
enzymes that hydroxylate 50-methylcytosine (Figueroa et al.,
2010; Turcan et al., 2012; Xu et al., 2011). a-ketoglutarate-
dependent TET activity produces 50-hydroxymethylcytosine.
This product can be an intermediate in either passive or active
DNA demethylation through pathways that are still under active
investigation. The biological relevance of TET inhibition by 2HG
has strong genetic evidence: neomorphic mutations of IDH1 or
IDH2 and TET2 loss-of-function mutations were found to be
mutually exclusive in a large AML cohort. Moreover, TET2
mutant AML samples displayed an overlapping DNA hyperme-
thylation signature with samples having IDH1 or IDH2mutations,
and shRNA knockdown of TET2 recapitulated the effect of IDH
mutant overexpression on blocking hematopoietic cell differen-
tiation (Figueroa et al., 2010).
The Oncometabolite 2HG Does More than Inhibit TET
Activity and DNA Demethylation
Similar to hematologicmalignancies, in gliomas and chondrosar-
comas IDH1 or IDH2 mutations have been linked with altered
DNA methylation profiles (Noushmehr et al., 2010; Pansuriya
et al., 2011; Turcan et al., 2012). However, in gliomas and chon-
drosarcomas, there is no evidence of mutations in TET enzymes.
This could potentially be due to the fact that redundant TET
enzymes are expressed in glial and chondrosarcoma precursor
cells, making it difficult to inactivate TET family function by
mutation in such cells. Alternatively, other chromatin-modifying
a-ketoglutarate-dependent dioxygenase enzymes may be in-hibited by 2HG in these cells. Although one initial report impli-
cated a broad array of enzymes that were affected by 2HG
(Xu et al., 2011), a later report suggested greater specificity of
2HG for some specific Jumonji C domain histone demethylases
(Chowdhury et al., 2011). Most recently, it has been reported that
the mark most altered with stable, as opposed to transient,
expression of IDH mutation is methylation at histone H3 lysine
9 (H3K9) (Lu et al., 2012). By studying the differentiation of
3T3-L1 fibroblasts into mature adipocytes, this study found
that inhibition of H3K9 demethylation by 2HG, or siRNA knock-
down of an H3K9 demethylase, was sufficient to block cell differ-
entiation in the absence of changes in DNA methylation. This
study also examined the effect of IDH mutation in immortalized
astrocytes and found that a progressive accumulation of H3K9
methylation preceded the increase in DNA methylation. TheCancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 303
2HG-induced alterations in histone and DNA methylation are
likely synergistic, and the precise relationship between these
marks is the focus of continued investigation. For now, these
findings provide further evidence that IDH mutation can impair
differentiation in nontransformed cells from multiple cells of
origin, and that this impairment is linked to 2HG-mediated epige-
netic dysregulation.
Non-cell-autonomous effects of 2HGmay also be important in
some tumors. 2HG can inhibit the prolyl hydroxylase that regu-
lates collagen synthesis (Xu et al., 2011). This inhibition could
impact the tumor microenvironment and partly account for the
diffuse nature of lower-grade gliomas. However, determination
of whether this and other effects of 2HG are ultimately important
for tumorigenesis will require careful future studies.
2HG Is Not the Only Oncometabolite
Will we find other novel oncometabolites like 2HG? We should
consider basing the search for new oncometabolites on those
metabolites already known to cause disease in pediatric inborn
errors of metabolism (IEMs). 2HG exemplifies how advances in
research on IEMs can inform research on cancer metabolism,
and vice versa. Methods developed by those studying 2HG
aciduria were used to demonstrate that R()-2HG (also known
as D-2HG) is the exclusive 2HG stereoisomer produced by
IDH1 and IDH2 mutants (Dang et al., 2009; Ward et al., 2010).
Likewise, following the discovery of 2HG-producing IDH2 R140
mutations in leukemia, researchers looked for and successfully
found germline IDH2 R140 mutations in D-2HG aciduria. IDH2
R140 mutations now account for nearly half of all cases of this
devastating disease (Kranendijk et al., 2010). While interest has
surrounded 2HG due to its apparent novelty as a metabolite
not found in normal nondiseased cells, there are situationswhere
2HG appears in the absence ofmetabolic enzymemutations. For
example, in human cells proliferating in hypoxia, a-ketoglutarate
can accumulate and be metabolized through an enhanced
reductive activity of wild-type IDH2 in the mitochondria, leading
to 2HG accumulation in the absence of IDHmutation (Wise et al.,
2011). The ability of 2HG to alter epigenetics may reflect its
evolutionary ancient status as a signal for elevated glutamine/
glutamate metabolism and/or oxygen deficiency.
With this broadened view of what constitutes an oncometa-
bolite, one could argue that the discoveries of two other onco-
metabolites, succinate and fumarate, preceded that of 2HG.
Loss-of-function mutations in the TCA cycle enzymes succinate
dehydrogenase (SDH) and fumarate hydratase (FH) have been
known for several years to occur in pheochromocytoma, para-
ganglioma, leiomyoma, and renal carcinoma. It was initially
hypothesized that these mutations contribute to cancer through
mitochondrial damage producing elevated ROS (Eng et al.,
2003). However, potential tumorigenic effects were soon linked
to the elevated levels of succinate and fumarate arising from
loss of SDH function and FH function, respectively. Succinate
was initially found to impair PHD2, the a-ketoglutarate-depen-
dent enzyme regulating HIF stability, through product inhibition
(Selak et al., 2005). Subsequent work confirmed that fumarate
could inhibit PHD2 (Isaacs et al., 2005) and that succinate could
also inhibit the related enzyme PHD3 (Lee et al., 2005). These
observations linked the elevated HIF levels observed in SDH-
and FH-deficient tumors to the activity of the succinate and304 Cancer Cell 21, March 20, 2012 ª2012 Elsevier Inc.fumarate metabolites. Recent work has suggested that fumarate
may have other important roles that predominate in FH defi-
ciency. For example, fumarate can modify cysteine residues to
inhibit a negative regulator of the Nrf2 transcription factor. This
posttranslational modification leads to the upregulation of anti-
oxidant response genes (Adam et al., 2011; Ooi et al., 2011).
There are still many unanswered questions regarding the
biology of SDH- and FH-deficient tumors. In light of the emerging
epigenetic effects of 2HG, it is intriguing that succinate has been
shown to alter histone demethylase activity in yeast (Smith et al.,
2007). Perhaps elevated succinate and fumarate resulting from
SDH and FH mutations can promote tumorigenesis in part
through epigenetic modulation.
Textbook Biochemical Pathways Often Do Not Apply
to Proliferating Cells
What has received little appreciation since the work of Krebs and
his colleagues is that for many proliferating cells, the major
problem is not how to maximize ATP yield, but rather how to
maximize the flux of carbon into macromolecular synthetic path-
ways. In fact, it was first demonstrated in 1973 that glycolysis in
proliferating cells is limited by the rate of ATP consumption and
not ATP production, as glycolytic enzymes can be inhibited
when ATP levels are high (Scholnick et al., 1973). Recent work
has revisited how proliferating cells maintain glycolytic flux by
either minimizing ATP production or enhancing ATP consump-
tion. The proposed alternative glycolytic pathway to get around
the PKM2 bottleneckmay be oneway to accomplish this (Vander
Heiden et al., 2010). In this alternative pathway, the high-energy
phosphate of PEP is transferred not to ADP but instead to a histi-
dine residue on an upstream glycolytic enzyme. This alternative
transfer therefore decouples the PEP/pyruvate conversion
from ATP production. Another study found that cells with acti-
vated PI3K/Akt upregulate the activity of ENTPD5, an endo-
plasmic reticulum enzyme involved in glycosylation reactions
and linked to ATP hydrolysis (Fang et al., 2010).
One pathway that supports cell proliferation and is not found in
most textbooks is the ability of TCA-cycle enzymes to facilitate
reductive carboxylation rather than oxidative metabolism. While
this may seem heretical, IDH-dependent reductive carboxylation
of a-ketoglutarate to isocitrate was described in early metabolic
literature (Ochoa, 1948) and has been investigated since then as
a way to produce citrate and fatty acids from a-ketoglutarate
derived from glutamine (Holleran et al., 1995; Ward et al., 2010;
Yoo et al., 2008). Recently, three independent reports implicated
IDH-dependent reductive carboxylation as playing a particularly
important role in proliferating cells that exhibit decreased flux of
glucose-derived pyruvate into the mitochondria. This occurs in
hypoxic cells or in cells harboring defects inmitochondrial oxida-
tive phosphorylation (Metallo et al., 2012; Mullen et al., 2012;
Wise et al., 2011). There are conflicting conclusions over whether
the reductive fluxof glutamine-derived carbon is primarily depen-
dent upon cytosolic IDH1 or mitochondrial IDH2. These findings
could all be correct if a mitochondrial-cytosolic NADPH shuttle
exists using these enzymes (Figure 6). Although NADPH mito-
chondrial-cytosolic shuttles have not been previously described,
it would allow high-energy electrons from NADPH in one com-
partment to be donated to a-ketoglutarate through reductive
carboxylation and then transported to the other compartment
Figure 6. Hypoxia and HIF-1 Activation Promote an Alternative
Pathway for Citrate Synthesis through Reductive Metabolism of
Glutamine
(A) In proliferating cells under normoxic conditions, citrate is synthesized from
both glucose and glutamine. Glucose carbon provides acetyl-CoA through the
activity of PDH. Glutamine carbon provides oxaloacetate through oxidative
mitochondrial metabolism dependent on NAD+. Glucose-derived acetyl-CoA
and glutamine-derived oxaloacetate condense to form citrate via the activity of
citrate synthase (CS). Citrate can be exported to the cytosol for lipid synthesis.
(B) In cells proliferating in hypoxia and/or with HIF-1 activation, glucose is
diverted away from mitochondrial acetyl-CoA and citrate production. Citrate
can be maintained through an alternative pathway of reductive carboxylation,
which we propose to rely on reverse flux of glutamine-derived a-ketoglutarate
through IDH2. This reverse flux in the mitochondria would promote electron
export from the mitochondria when the activity of the electron transport chain
is inhibited because of the lack of oxygen as an electron acceptor. Mito-
chondrial reverse flux can be accomplished byNADH conversion to NADPHby
mitochondrial transhydrogenase and the resulting NADPH use in a-ketoglu-
tarate carboxylation. When citrate/isocitrate is exported to the cytosol, some
may be metabolized in the oxidative direction by IDH1 and contribute to
a shuttle that produces cytosolic NADPH.in the form of isocitrate/citrate for oxidation and regeneration of
a-ketoglutarate and NADPH. Further work is needed to test this
concept, but knowledge regarding cellular redox suggests the
reductive flux is likely to occur in the mitochondria. Mitochondria
have a high NADH:NAD+ ratio, particularly in hypoxia (Chance
and Thorell, 1959; Frezza et al., 2011), and NADH can be con-
verted toNADPHwithin themitochondria via a transhydrogenase
that is absent from the cytosol (Rydstro¨m, 2006).Unlike ATP, cytosolic NADPHmight be limiting for cell prolifer-
ation. It is critical for providing reducing equivalents for fatty acid
and cholesterol biosynthesis, as well as for modulating oxidative
stress. Historically, the oxidative pentose phosphate pathway,
branching off glycolysis at glucose-6-phosphate dehydroge-
nase (G6PD), has been considered the major NADPH-producing
pathway. However, we offer that the repeated human experi-
ment should be considered: millions of men are affected by the
X-linked disorder of G6PD deficiency, yet cohort studies have
not detected a decrease in cancer incidence in G6PD-deficient
men (Cocco et al., 1998; Ferraris et al., 1988), and smaller case
control studies have also failed to demonstrate a relationship
(Forteleoni et al., 1988; Pisano et al., 1991). These studies
focused on men with the Mediterranean variant of G6PD, an
allele demonstrating severe enzyme deficiency with less than
10% of normal activity. The relationship between other
disease-associated G6PD variants and cancer has not been
rigorously tested. Notably, Ferraris et al. also examined females
with mosaicism for the Mediterranean variant of G6PD (due to
random X inactivation) who developed clonal hematological
disorders. Neoplastic clones did not demonstrate preferential
expression of the wild-type G6PD allele. Collectively, these
data raise the possibility that significant flux through G6PD to
generate NADPH is not necessarily critical for cell proliferation
or tumorigenesis. While this hypothesis deserves further study,
it would account for the observed propensity of tumor cells to
synthesize pentose phosphates through a G6PD-independent
pathway (Boros et al., 2000; Zhao et al., 2010). It would also fit
with the importance of glucose carbon being metabolized
through other branches of glycolytic metabolism, including
serine synthesis (as discussed above) and the hexosamine
pathway (Wellen et al., 2010). However, exactly which alternative
NADPH-generating pathways are most important remain
unclear. Further work in this area would benefit from improved
methods for measuring NADPH.
Challenges Ahead for Studying the Metabolic Hallmarks
of Cancer
Despite rapid technological advances in studying cell metabo-
lism, we remain unable to reliably distinguish cytosolic metabo-
lites from those in the mitochondria and other compartments.
Current fractionation methods often lead to metabolite leakage.
Even within one subcellular compartment, there may be distinct
pools of metabolites resulting from channeling between meta-
bolic enzymes. A related challenge lies in the quantitative
measurement of metabolic flux, i.e., measuring the movement
of carbon, nitrogen, and other atoms through metabolic path-
ways rather than simply measuring the steady-state levels of
individual metabolites. While critical fluxes have been quantified
in cultured cancer cells, and methods for these analyses
continue to improve (DeBerardinis et al., 2007; Mancuso et al.,
2004; Yuan et al., 2008), many obstacles remain, such as cellular
compartmentalization and the reliance of most cell culture on
complex, incompletely defined media.
Non-cell-autonomous effects of tumor metabolism represent
another emerging challenge. For example, lactate produced
by tumor cells can acidify the surrounding microenvironment
and potentially promote tumor invasion, and some tumors
may exhibit a symbiosis between lactate-producing cells andCancer Cell 21, March 20, 2012 ª2012 Elsevier Inc. 305
lactate-consuming cells (Sonveaux et al., 2008). In addition, fatty
acid exchange between omental adipocytes and ovarian carci-
noma cells has been documented (Nieman et al., 2011). These
areas appear ripe for further study.
Over the past decade, the study of metabolism has returned to
its rightful place at the forefront of cancer research. Although
Warburg was wrong about mitochondria, he was prescient in
his focus on metabolism. Data now support the concepts that
altered metabolism results from active reprogramming by
altered oncogenes and tumor suppressors, and that metabolic
adaptations can be clonally selected during tumorigenesis.
Altered metabolism should now be considered a core hallmark
of cancer. There is much work to be done.
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